To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with malignant hematologic diseases after single-unit unrelated cord blood transplantation (sUCBT).
Definite diagnosis of malignant hematologic disease before transplantation, age, gender and race are not limited;
Participants were required to have achieved complete remission with negative minimal residual disease (MRD) prior to transplantation;
Participants who are proposed to receive sUCBT for the first time;
Eastern Cooperative Oncology Group (ECOG) score 0-2;
Those with severe organ dysfunction or disease, such as severe disease and dysfunction of the heart, liver, kidneys and pancreas;
Any life-threatening disease, physical condition, or organ system dysfunction that, in the opinion of the investigator, may compromise participant safety and put the results of the study at unnecessary risk; drug-dependent individuals; participants with uncontrolled psychiatric disorders; and individuals with cognitive dysfunction;
Participants in other clinical studies that may affect aGVHD within 3 months;
Those whom the investigator considers unsuitable for enrollment (e.g., those who anticipate that patients will not be able to adhere to the examination and treatment due to financial and other issues).
Parallel
Time of umbilical cord blood infusion
Procedure/SurgeryRandomization of patients according to the time of umbilical cord blood infusion
The incidence of grade III to IV aGVHD
The primary endpoint of the study will be the development of aGVHD in the first 100 days post-transplant. Acute GVHD was graded according to the Mount Sinai Acute GVHD International Consortium criteria.
The incidence of grade II to IV aGVHD
The cumulative incidence of grade II to IV aGVHD in the first 100 days post-transplant. aGVHD was graded according to the Mount Sinai Acute GVHD International Consortium criteria.
The cumulative incidence of neutrophil engraftment at 42 days after transplantation
neutrophil engraftment time was defined as the first of three consecutive days during which the neutrophil count was at least 0.5×10\^9/L.
The cumulative incidence of platelet engraftment at 60 days after transplantation
Platelet engraftment is defined as independence from platelet transfusion for at least 7 days with a platelet count of more than ≥ 20 × 10\^9/L.
The cumulative incidence of transplant-related mortality at 360 days after transplantation
The cumulative incidence of transplant-related mortality at 360 days after transplantation
Click on the lead sponsor to view all of their trials.
